Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Phoenix Molecular Designs
- Target Recruit Count
- 61
- Registration Number
- NCT04115306
- Locations
- ๐บ๐ธ
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
๐บ๐ธUniversity of California, Los Angeles (UCLA), Los Angeles, California, United States
๐บ๐ธMoffitt Cancer Center, Tampa, Florida, United States
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Effector Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT04092673
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center- Westchester, Harrison, New York, United States
๐บ๐ธStanford University, Palo Alto, California, United States
๐บ๐ธSTART Midwest, Grand Rapids, Michigan, United States
A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT04060862
- Locations
- ๐บ๐ธ
University of Chicago Medical Center, Chicago, Illinois, United States
๐จ๐ฆHopital du Saint Sacrement, Quebec City, Quebec, Canada
๐บ๐ธDana-Farber Cancer Institute; GYN Oncology, Boston, Massachusetts, United States
Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-08-16
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 367
- Registration Number
- NCT04059484
- Locations
- ๐บ๐ฆ
Investigational Site Number : 8040001, Kryvyi Rih, Ukraine
๐ฌ๐ทInvestigational Site Number : 3000004, Thessaloniki, Greece
๐ง๐ทHospital de Clinicas de Porto Alegre - HCPA Site Number : 0760001, Porto Alegre, Rio Grande Do Sul, Brazil
Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.
- Conditions
- Interventions
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 172
- Registration Number
- NCT04053322
- Locations
- ๐ซ๐ท
Centre Henri-Becquerel, Rouen, France
๐ซ๐ทInstitut de Cancerologie de Montpellier, Montpellier, France
A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-07-24
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 4
- Registration Number
- NCT04031885
- Locations
- ๐บ๐ธ
Yuma Regional Cancer Center, Yuma, Arizona, United States
๐บ๐ธComprehensive Blood and Cancer Center, Bakersfield, California, United States
๐บ๐ธCompassionate Cancer Care Medical Group Inc, Riverside, California, United States
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
- Conditions
- Interventions
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 77
- Registration Number
- NCT03959891
- Locations
- ๐บ๐ธ
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT03939897
- Locations
- ๐บ๐ธ
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
๐บ๐ธBellevue Hospital Center, New York, New York, United States
๐บ๐ธUC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 357
- Registration Number
- NCT03927456
- Locations
- ๐จ๐ณ
Chinese Academy of Medical Science, Beijing, Beijing, China
FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study
- Conditions
- Interventions
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Frederic Amant
- Target Recruit Count
- 17
- Registration Number
- NCT03926936
- Locations
- ๐ณ๐ฑ
Gynaecological Oncology, Radboudumc, Nijmegen, Gelderland, Netherlands
๐ง๐ชUZ Gent, Gent, Belgium
๐ณ๐ฑmedical Oncology, Maastricht University Medical Centrum+, Maastricht, Limburg, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.